MA55316A - Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 - Google Patents
Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1Info
- Publication number
- MA55316A MA55316A MA055316A MA55316A MA55316A MA 55316 A MA55316 A MA 55316A MA 055316 A MA055316 A MA 055316A MA 55316 A MA55316 A MA 55316A MA 55316 A MA55316 A MA 55316A
- Authority
- MA
- Morocco
- Prior art keywords
- blocking agents
- therapies including
- including ctla
- cancer multi
- cancer
- Prior art date
Links
- 102000008203 CTLA-4 Antigen Human genes 0.000 title 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 title 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 title 1
- 229940045513 CTLA4 antagonist Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000012270 PD-1 inhibitor Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940121655 pd-1 inhibitor Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817749P | 2019-03-13 | 2019-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55316A true MA55316A (fr) | 2022-01-19 |
Family
ID=72426465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055316A MA55316A (fr) | 2019-03-13 | 2020-03-10 | Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12358986B2 (en]) |
| EP (1) | EP3937979A4 (en]) |
| JP (1) | JP7581225B2 (en]) |
| KR (1) | KR20210141539A (en]) |
| CN (1) | CN113631189A (en]) |
| AU (1) | AU2020234785A1 (en]) |
| BR (1) | BR112021017892A8 (en]) |
| CA (1) | CA3132198A1 (en]) |
| MA (1) | MA55316A (en]) |
| MX (1) | MX2021010997A (en]) |
| WO (1) | WO2020185722A2 (en]) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202203973A (zh) | 2020-04-22 | 2022-02-01 | 美商默沙東藥廠 | 對介白素-2受體βγc二聚體具偏性且結合至非肽、水溶性聚合物之人類介白素-2結合物 |
| CA3206241A1 (en) * | 2021-01-29 | 2022-01-28 | Guoqing Cao | Antigen binding protein and use thereof |
| KR20230171456A (ko) * | 2021-04-14 | 2023-12-20 | 아케소 파마슈티컬스, 인코포레이티드 | 항-종양 치료에서의 항체의 용도 |
| CN117203235A (zh) * | 2021-04-21 | 2023-12-08 | 和铂医药(上海)有限责任公司 | 结合ctla-4的抗体及其用途 |
| KR20230110141A (ko) | 2022-01-14 | 2023-07-21 | 영남대학교 산학협력단 | PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도 |
| JP2025516590A (ja) * | 2022-05-12 | 2025-05-30 | ビオンテック・ソシエタス・エウロパエア | プログラム死－１タンパク質に対するモノクローナル抗体および医薬におけるその使用 |
| WO2025042997A1 (en) * | 2023-08-21 | 2025-02-27 | Agenus Inc. | Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP3502133A1 (en) | 2002-09-27 | 2019-06-26 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| EP2439272A3 (en) | 2005-05-09 | 2013-07-31 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| WO2008071447A2 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| ME02093B (me) | 2007-06-18 | 2014-04-30 | N V Organon | Antitijela za humani receptor programirane smrti pd-1 |
| CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2009030285A1 (en) | 2007-09-07 | 2009-03-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
| WO2011120135A1 (en) | 2010-03-29 | 2011-10-06 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
| PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| EP4324480A3 (en) | 2013-05-20 | 2024-05-08 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2949121A1 (en) * | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CN107250157B (zh) | 2014-11-21 | 2021-06-29 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| US10196445B1 (en) | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| EP3377526A1 (en) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | PD1/CTLA4 Binders |
| DK3377534T3 (da) * | 2015-11-18 | 2025-08-18 | Bristol Myers Squibb Company | Behandling af lungecancer ved hjælp af en kombination af et anti-pd-1-antistof og et anti-ctla-4-antistof |
| EP3377527A1 (en) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | Ctla4 binders |
| JO3744B1 (ar) | 2015-11-18 | 2021-01-31 | Merck Sharp & Dohme | مواد ربط لـpd1 و/ أو lag3 |
| US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
| AU2017355446A1 (en) | 2016-11-03 | 2019-05-02 | Bristol-Myers Squibb Company | Activatable anti-CTLA-4 antibodies and uses thereof |
| US20200115451A1 (en) | 2017-03-31 | 2020-04-16 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
| EP3618866A4 (en) * | 2017-05-02 | 2021-07-14 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH ANTIBODY ANTI-RECEPTOR PROGRAMMED DEATH 1 (PD-1) AND THEIR METHODS OF USE |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| MA51844A (fr) * | 2018-02-13 | 2021-05-19 | Merck Sharp & Dohme | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 |
-
2020
- 2020-03-10 AU AU2020234785A patent/AU2020234785A1/en active Pending
- 2020-03-10 CA CA3132198A patent/CA3132198A1/en active Pending
- 2020-03-10 MX MX2021010997A patent/MX2021010997A/es unknown
- 2020-03-10 JP JP2021553837A patent/JP7581225B2/ja active Active
- 2020-03-10 US US17/436,857 patent/US12358986B2/en active Active
- 2020-03-10 BR BR112021017892A patent/BR112021017892A8/pt unknown
- 2020-03-10 CN CN202080020847.XA patent/CN113631189A/zh active Pending
- 2020-03-10 MA MA055316A patent/MA55316A/fr unknown
- 2020-03-10 EP EP20770048.5A patent/EP3937979A4/en active Pending
- 2020-03-10 WO PCT/US2020/021783 patent/WO2020185722A2/en active IP Right Grant
- 2020-03-10 KR KR1020217032365A patent/KR20210141539A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210141539A (ko) | 2021-11-23 |
| JP2022525071A (ja) | 2022-05-11 |
| BR112021017892A2 (en]) | 2021-12-07 |
| EP3937979A4 (en) | 2023-03-08 |
| EP3937979A2 (en) | 2022-01-19 |
| CA3132198A1 (en) | 2020-09-17 |
| CN113631189A (zh) | 2021-11-09 |
| MX2021010997A (es) | 2021-10-01 |
| US20220411507A1 (en) | 2022-12-29 |
| US12358986B2 (en) | 2025-07-15 |
| JP7581225B2 (ja) | 2024-11-12 |
| AU2020234785A1 (en) | 2021-08-19 |
| WO2020185722A3 (en) | 2020-11-12 |
| WO2020185722A2 (en) | 2020-09-17 |
| BR112021017892A8 (pt) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55316A (fr) | Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 | |
| MA55565A (fr) | Agents de dégradation de stat et leurs utilisations | |
| IL286291A (en) | Compounds and conjugates thereof | |
| DK4015003T3 (da) | Forbedret antistof-oligonukleotid-konjugat | |
| SMT202400472T1 (it) | Anticorpo anti-cdh6 e coniugato anticorpo anti-cdh6-farmaco | |
| EP4041262A4 (en) | Targeted bifunctional degraders | |
| MA51447A (fr) | Conjugué anticorps monoclonal-médicament dirigé contre bcma | |
| EP3664829A4 (en) | LIAISON OFFICERS AT PD-1 AND PD-L1 | |
| PL3794042T3 (pl) | Koniugat przeciwciało-lek przeciwciało skierowane przeciwko muc1 - eksatekan | |
| IL286473A (en) | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer | |
| CY1119510T1 (el) | Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης | |
| MA49042A (fr) | Polythérapies ciblant pd-1, tim-3 et lag-3 | |
| EP4041462A4 (en) | ANTIMICROBIAL PARTICLE DETECTORS | |
| EP3389699A4 (en) | CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODIES TO HUMAN CTLA4 AND USES THEREOF | |
| EP3423664A4 (en) | ADJUSTING MECHANISMS, MANAGING THEM AND RELATED METHODS | |
| EP3870162A4 (en) | SSAO INHIBITORS AND USES THEREOF | |
| EP3778953A4 (en) | HOT DIP GALVANIZED ALLOY STEEL SHEET | |
| EP3946456A4 (en) | Targeted synergistic cancer immunotherapy | |
| IL287008A (en) | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease | |
| DE112020003310A5 (de) | Einkaufs- und bezahlsystem | |
| IT201900020514A1 (it) | Dispositivo di irrigazione e/o fertirrigazione | |
| IL277979A (en) | Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment | |
| IL270948A (en) | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer | |
| EP3780979C0 (en) | MEN'S UNDERWEAR | |
| DK3547330T3 (da) | Strålebeskyttelsesbeklædningssystem |